{"id":1018734,"date":"2026-11-09T09:34:01","date_gmt":"2026-11-09T14:34:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/"},"modified":"2026-11-09T09:34:01","modified_gmt":"2026-11-09T14:34:01","slug":"iambic-to-participate-in-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/","title":{"rendered":"Iambic to participate in Jefferies Global Healthcare Conference"},"content":{"rendered":"

\nCo-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026
\n<\/h2>\n
\n

SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) — Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced that Iambic Co-Founder and CEO Tom Miller, PhD will attend the Jefferies Global Healthcare Conference, taking place November 16-19 in London. Dr. Miller will participate in a panel on AI in drug discovery on November 18 at 2:00 PM GMT.<\/p>\n

Now in its 17th<\/sup> year, Jefferies Global Healthcare Conference is Europe\u2019s largest healthcare-focused conference featuring leaders in pharma, biopharma, biotech, healthcare, and health IT.<\/p>\n

\u201cThe greatest opportunity for AI in drug discovery is to fundamentally improve the probability of developing successful medicines by integrating insights across chemistry, biology, and clinical development,\u201d said Tom Miller, PhD, Co-Founder and CEO of Iambic. \u201cAt Iambic, we are translating this vision into reality through our integrated molecular superintelligence platform and a growing clinical pipeline. I look forward to discussing how the industry can move beyond the promise of AI to delivering meaningful advances for patients.\u201d<\/p>\n

About Iambic<\/strong>
Iambic\u2019s mission is to make better technology for better medicines. By utilizing molecular superintelligence \u2014 integrating proprietary AI with automated, scalable chemistry and biology experimentation \u2014 our platform is designed to address the totality of drug discovery and development. We believe the utility of our platform is demonstrated by the discovery of IAM1363, a novel drug candidate advanced to clinic in approximately two years, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building an engine that is designed to power the future of medicine. | iambic.ai<\/p>\n

Forward-Looking Statements<\/strong>
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such statements include, but are not limited to, statements regarding Iambic\u2019s participation in the 2026 Jefferies Global Healthcare Conference, the potential of its platform, and its pipeline and strategy. These statements are based on numerous assumptions and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including other risks described under \u201cRisk Factors\u201d in Iambic\u2019s final prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) on October 15, 2026, and in Iambic\u2019s subsequent filings with the Securities and Exchange Commission. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. These forward-looking statements are made as of the date of this press release, and Iambic assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.<\/p>\n

\n Media:<\/strong>
\n
Amanda Guisbond
Head of Communications, Iambic
amanda.guisbond@iambic.ai<\/a><\/p>\n

\n Investors:<\/strong>
\n
Tiao Guan
Sr. Director, FP&A and Investor Relations, Iambic
tiao.guan@iambic.ai<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026 SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) — Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced that Iambic Co-Founder and CEO Tom Miller, PhD will attend the Jefferies Global Healthcare Conference, taking place November 16-19 in London. Dr. Miller will participate in a panel on AI in drug discovery on November 18 at 2:00 PM GMT. Now in its 17th year, Jefferies Global Healthcare Conference is Europe\u2019s largest healthcare-focused conference featuring leaders in pharma, biopharma, biotech, healthcare, and health IT. \u201cThe greatest opportunity for AI in drug discovery is to fundamentally improve the probability of … <\/p>\n

Continue reading “Iambic to participate in Jefferies Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018734","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIambic to participate in Jefferies Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iambic to participate in Jefferies Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026 SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) — Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced that Iambic Co-Founder and CEO Tom Miller, PhD will attend the Jefferies Global Healthcare Conference, taking place November 16-19 in London. Dr. Miller will participate in a panel on AI in drug discovery on November 18 at 2:00 PM GMT. Now in its 17th year, Jefferies Global Healthcare Conference is Europe\u2019s largest healthcare-focused conference featuring leaders in pharma, biopharma, biotech, healthcare, and health IT. \u201cThe greatest opportunity for AI in drug discovery is to fundamentally improve the probability of … Continue reading "Iambic to participate in Jefferies Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T14:34:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iambic to participate in Jefferies Global Healthcare Conference\",\"datePublished\":\"2026-11-09T14:34:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/\"},\"wordCount\":545,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/\",\"name\":\"Iambic to participate in Jefferies Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=\",\"datePublished\":\"2026-11-09T14:34:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iambic-to-participate-in-jefferies-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iambic to participate in Jefferies Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iambic to participate in Jefferies Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Iambic to participate in Jefferies Global Healthcare Conference - Market Newsdesk","og_description":"Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026 SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) — Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced that Iambic Co-Founder and CEO Tom Miller, PhD will attend the Jefferies Global Healthcare Conference, taking place November 16-19 in London. Dr. Miller will participate in a panel on AI in drug discovery on November 18 at 2:00 PM GMT. Now in its 17th year, Jefferies Global Healthcare Conference is Europe\u2019s largest healthcare-focused conference featuring leaders in pharma, biopharma, biotech, healthcare, and health IT. \u201cThe greatest opportunity for AI in drug discovery is to fundamentally improve the probability of … Continue reading \"Iambic to participate in Jefferies Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T14:34:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iambic to participate in Jefferies Global Healthcare Conference","datePublished":"2026-11-09T14:34:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/"},"wordCount":545,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/","name":"Iambic to participate in Jefferies Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=","datePublished":"2026-11-09T14:34:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkzNiM3OTUzMTEyIzIzMjQxODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iambic-to-participate-in-jefferies-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iambic to participate in Jefferies Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018734"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018734\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}